Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 41.87 -0.74 (-1.74%) Market Cap: 3.48 Bil Enterprise Value: 3.17 Bil PE Ratio: 0 PB Ratio: 25.24 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript

Nov 16, 2020 / 08:00PM GMT
Release Date Price: $118.67 (+1.24%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Okay. Well, thank you, everyone. My name is Gena Wang. I'm a SMid cap biotech analyst at Barclays.

It is my great pleasure to introduce our next presenting company, Ultragenyx. On the screen with me is Emil Kakkis, President and Chief Executive Officer and a Co-Founder of the company.

Emil, I will hand it over to you.

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Well, thank you, Gena. Thank you for having us on the call today. Happy to be -- give you a brief update on Ultragenyx for just a couple of minutes, and then we can go into any questions you may have.

It's been a remarkable year for Ultragenyx as a company. It's our tenth year since founding. And in that year, we completed 2 product approvals for Dojolvi and the TIO indication for Crysvita. We continue to manage the significant launch of both products that we were approved and now the 2 products and despite the COVID situation. We attribute it to our field teams and the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot